Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness
Key facts
- Where
- Toronto, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT07339943, who can take part
Where in Canada
- University Health Network - Princess Margaret Cancer CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT07339943
- Record updated
- 25 September 2026
- Original description
This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk prostate cancer (PCa) to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation Therapy) for their disease.Read full original descriptionShow less
Micro-ultrasound-Guided Focal Laser Ablation (MicroUSgFLA) Treatment for Management of Intermediate-Risk Prostate Cancer: Evaluation of Safety and Effectiveness
This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk prostate cancer (PCa) to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation Therapy) for their disease.
Inclusion: Men 40-80 years of age; Histologically-proven intermediate-risk PCa (Gleason score 7, primary grade ≤ 4); PCa clinical stage T1c or T2; MRI/MicroUS site suspicious for cancer or cancer mapped to one prostate lobe; Maximum dimension of MRI/MicroUS visible tumour ≤15mm; Suspicious site on Prostate MRI/MicroUS must coincide with sector positive for cancer on biopsy; Prostate specific antigen (PSA) level < 15 ng/mL; IPSS, ICIQ-UI-SF, IIEF-15 questionnaires completed prior to the procedure; Life expectancy of greater than 10 years, based on co-morbidity not related to PCa.
Exclusion: Patients medically unfit for focal therapy of the prostate; Patients who have received androgen suppression therapy; Patients who have received or are receiving chemotherapy for prostate carcinoma; Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive) including HIFU, TUNA, RITA, microwave, cryotherapy or any curative treatment; Patients who have undergone radiation therapy for PCa or to the pelvis; Patients who have participated in a clinical study and/or received treatment with an investigational treatment and/or product within the past 90 days; Any condition or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies); Patients with a history of non-compliance with medical therapy and/or medical recommendations; Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition; Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent); Maximum dimension of MRI/MicroUS visible tumour > 15 mm; Patients who are unwilling or unable to give informed consent; Patients who are unwilling or unable to complete the patient self-assessment questionnaires.